#ESMO_Congress
LightNews LightNews
newsen.bsky.social
Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress#USA#San_Diego#Inhibrx#ESMO_Congress#Ewing_Sarcoma
Inhibrx Biosciences Set to Showcase Innovative Research at ESMO Congress
Inhibrx Biosciences is preparing to present groundbreaking findings on a novel drug combination for Ewing Sarcoma at the ESMO conference in March 2026.
third-news.com
March 2, 2026 at 9:06 PM
newsen.bsky.social
Hengrui Pharma Shines at ESMO 2025 with Its Groundbreaking Oncology Innovations#Germany#Berlin#Hengrui_Pharma#oncology_research#ESMO_Congress
Hengrui Pharma Shines at ESMO 2025 with Its Groundbreaking Oncology Innovations
At the ESMO 2025 Congress, Hengrui Pharma unveiled 46 innovative studies, solidifying its role in global oncology research and patient care.
third-news.com
October 20, 2025 at 6:24 AM
newsen.bsky.social
Significant Advancements in Lung Cancer Treatment with Sacituzumab Tirumotecan from Recent Clinical Trials#China#Chengdu#Lung_Cancer#sacituzumab_tirumotecan#ESMO_Congress
Significant Advancements in Lung Cancer Treatment with Sacituzumab Tirumotecan from Recent Clinical Trials
Recent results from the Phase 3 OptiTROP-Lung04 trial for sacituzumab tirumotecan show promising benefits for lung cancer patients, marking a pivotal moment in treatment options.
third-news.com
October 20, 2025 at 2:13 AM
newsen.bsky.social
Caris Life Sciences Showcases Innovative Cancer Research at ESMO 2025 Congress#United_States#Caris_Life_Sciences#Irving#Precision_Medicine#ESMO_Congress
Caris Life Sciences Showcases Innovative Cancer Research at ESMO 2025 Congress
Caris Life Sciences is set to present six groundbreaking studies at the ESMO 2025 Congress, showcasing advancements in precision medicine and multiomics.
third-news.com
October 14, 2025 at 1:35 PM
newsen.bsky.social
Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025#India#Mumbai#Lupin_Limited#ESMO_Congress#LNP3693
Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025
Lupin Limited is set to present critical Phase 1 data on LNP3693, a STING agonist, at the ESMO Congress 2025, highlighting potential advances in cancer treatment.
third-news.com
October 13, 2025 at 9:44 AM
newsen.bsky.social
Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin#India#Mumbai#Lupin_Limited#ESMO_Congress#LNP3693
Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin
Lupin Limited is set to present data from its Phase 1 trial of LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, showcasing its potential in treating advanced solid tumors.
third-news.com
October 13, 2025 at 9:43 AM
newsen.bsky.social
Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025#India#Mumbai#Lupin_Limited#ESMO_Congress#LNP3693
Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025
Lupin Limited announces the presentation of Phase-1 findings for LNP3693 at the ESMO Congress 2025, highlighting its potential in cancer treatment.
third-news.com
October 13, 2025 at 9:42 AM
newsen.bsky.social
Leap Therapeutics to Showcase Final Clinical Findings of DeFianCe Study at ESMO Congress 2025#USA#Cambridge#Leap_Therapeutics#ESMO_Congress#DKK1_antibody
Leap Therapeutics to Showcase Final Clinical Findings of DeFianCe Study at ESMO Congress 2025
Leap Therapeutics, Inc. is set to present the final clinical outcomes from the DeFianCe study, featuring their innovative anti-DKK1 antibody, at ESMO 2025.
third-news.com
September 25, 2025 at 11:17 AM
newsen.bsky.social
Lutris Pharma to Share Results from Phase 2 Trial of LUT014 Gel for Treating EGFRI-Induced Acneiform Rash at ESMO 2025#Israel#Tel_Aviv#Lutris_Pharma#LUT014#ESMO_Congress
Lutris Pharma to Share Results from Phase 2 Trial of LUT014 Gel for Treating EGFRI-Induced Acneiform Rash at ESMO 2025
Lutris Pharma is set to present data from its Phase 2 trial of LUT014 gel, aimed at treating acneiform rash induced by EGFR inhibitors, at ESMO 2025.
third-news.com
June 17, 2025 at 11:13 AM